[1] |
SUNG H, FERLAY J, SIEGELR L, et al. Global cancer statistics 2020: GLOBOCANestimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2021, 71(3):209-249. doi: 10.3322/caac.21660 |
[2] |
RAWLA P, SUNKARA T, BARSOUK A. Epidemiology of colorectal cancer: incidence, mortality, survival, and risk factors[J]. PrzGastroenterol, 2019, 14(2):89-103. |
[3] |
KIMJ Y, HE F, KARIN M. From liver fat to cancer: perils of the western diet[J]. Cancers, 2021, 13(5):1095. doi: 10.3390/cancers13051095 |
[4] |
JIA F J, YU Q, WANG R L, et al. Optimized antimicrobial peptide jelleine-I derivative Br-J-I inhibits Fusobacteriumnucleatum to suppress colorectal cancer progression[J]. Int J Mol Sci, 2023, 24(2):1469. doi: 10.3390/ijms24021469 |
[5] |
BENSONA B, VENOOKAP, AL-HAWARYM M, et al. Colon cancer, version 2.2021, NCCNclinicalpracticeguidelines in oncology[J]. J NatlComprCancNetw, 2021, 19(3):329-359. |
[6] |
KELLAND L. The resurgence of platinum-based cancer chemotherapy[J]. Nat Rev Cancer, 2007, 7(8):573-584. doi: 10.1038/nrc2167 |
[7] |
WALKOC M, LINDLEY C. Capecitabine: a review[J]. Clin Ther, 2005, 27(1):23-44. doi: 10.1016/j.clinthera.2005.01.005 |
[8] |
CHU D K, ZHANG Z X, LI Y M, et al. Prediction of colorectal cancer relapse and prognosis by tissue mRNA levels of NDRG2[J]. Mol Cancer Ther, 2011, 10(1):47-56. doi: 10.1158/1535-7163.MCT-10-0614 |
[9] |
DAHAN L, SADOK A, FORMENTOJ L, et al. Modulation of cellular redox state underlies antagonism between oxaliplatin and cetuximab in human colorectal cancer cell lines[J]. Br J Pharmacol, 2009, 158(2):610-620. doi: 10.1111/j.1476-5381.2009.00341.x |
[10] |
FAÏS T, DELMAS J, COUGNOUX A, et al. Targeting colorectal cancer-associated bacteria: a new area of research for personalized treatments[J]. Gut Microbes, 2016, 7(4):329-333. doi: 10.1080/19490976.2016.1155020 |
[11] |
HARUKI K, KOSUMI K, HAMADA T, et al. Association of autophagy status with amount of Fusobacteriumnucleatum in colorectal cancer[J]. J Pathol, 2020, 250(4):397-408. doi: 10.1002/path.5381 |
[12] |
CHEN Y Y, CHEN Y, ZHANG J X, et al. Fusobacteriumnucleatumpromotesmetastasis in colorectal cancer by activating autophagy signaling via the upregulation of CARD3expression[J]. Theranostics, 2020, 10(1):323-339. doi: 10.7150/thno.38870 |
[13] |
MÁRMOL I, SÁNCHEZ-DE-DIEGO C, PRADILLADIESTE A, et al. Colorectal carcinoma: ageneral overview and future perspectives in colorectal cancer[J]. Int J Mol Sci, 2017, 18(1):197. doi: 10.3390/ijms18010197 |
[14] |
GUO S H, CHEN J, CHEN F F, et al. Exosomes derived from Fusobacteriumnucleatum-infected colorectal cancer cells facilitate tumour metastasis by selectively carrying miR-1246/92b-3p/27a-3p and CXCL16[J]. Gut, 2020: gutjnl-gu2020-321187. |
[15] |
XUE Y, XIAO H, GUO S H, et al. Indoleamine 2, 3-dioxygenase expression regulates the survival and proliferation of Fusobacteriumnucleatum in THP-1-derived macrophages[J]. Cell Death Dis, 2018, 9(3):355. doi: 10.1038/s41419-018-0389-0 |
[16] |
BROOK I. Fusobacterial infections in children[J]. Curr Infect Dis Rep, 2013, 15(3):288-294. doi: 10.1007/s11908-013-0340-6 |
[17] |
COCHRANE K, ROBINSONA V, HOLTR A, et al. A survey of Fusobacteriumnucleatum genes modulated by host cell infection[J]. MicrobGenom, 2020, 6(2):e000300. |
[18] |
HASHEMI GORADEL N, HEIDARZADEH S, JAHANGIRI S, et al. Fusobacteriumnucleatum and colorectal cancer: a mechanistic overview[J]. J Cell Physiol, 2019, 234(3):2337-2344. doi: 10.1002/jcp.27250 |
[19] |
KOSTICA D, CHUN E, ROBERTSON L, et al. Fusobacteriumnucleatum potentiates intestinal tumorigenesis and modulates the tumor-immune microenvironment[J]. Cell Host Microbe, 2013, 14(2):207-215. doi: 10.1016/j.chom.2013.07.007 |
[20] |
HUI B Q, ZHOU C C, XU Y T, et al. Exosomes secreted by Fusobacteriumnucleatum-infected colon cancer cells transmit resistance to oxaliplatin and 5-FU by delivering hsa_circ_0004085[J]. J Nanobiotechnology, 2024, 22(1):62. doi: 10.1186/s12951-024-02331-9 |